{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T14:49:36Z","timestamp":1793371776636,"version":"4.5.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2024,1,15]],"date-time":"2024-01-15T00:00:00Z","timestamp":1705276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,15]],"date-time":"2024-01-15T00:00:00Z","timestamp":1705276800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Chem Biol"],"published-print":{"date-parts":[[2024,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>A major challenge in creating universal influenza vaccines is to focus immune responses away from the immunodominant, variable head region of hemagglutinin (HA-head) and toward the evolutionarily conserved stem region (HA-stem). Here we introduce an approach to control antigen orientation via site-specific insertion of aspartate residues that facilitates antigen binding to alum. We demonstrate the generalizability of this approach with antigens from Ebola, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and influenza viruses and observe enhanced neutralizing antibody responses in all cases. We then reorient an H2 HA in an \u2018upside-down\u2019 configuration to increase the exposure and immunogenicity of HA-stem. The reoriented H2 HA (reoH2HA) on alum induced stem-directed antibodies that cross-react with both group 1 and group 2 influenza A subtypes. Electron microscopy polyclonal epitope mapping (EMPEM) revealed that reoH2HA (group 1) elicits cross-reactive antibodies targeting group 2 HA-stems. Our results highlight antigen reorientation as a generalizable approach for designing epitope-focused vaccines.<\/jats:p>","DOI":"10.1038\/s41589-023-01529-6","type":"journal-article","created":{"date-parts":[[2024,1,15]],"date-time":"2024-01-15T11:02:25Z","timestamp":1705316545000},"page":"1012-1021","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":43,"title":["Vaccine design via antigen reorientation"],"prefix":"10.1038","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0483-8719","authenticated-orcid":false,"given":"Duo","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua J.","family":"Carter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunfeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley","family":"Utz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Payton A. B.","family":"Weidenbacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaogeng","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1365-4279","authenticated-orcid":false,"given":"Mrinmoy","family":"Sanyal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bali","family":"Pulendran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher O.","family":"Barnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6503-4541","authenticated-orcid":false,"given":"Peter S.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,15]]},"reference":[{"key":"1529_CR1","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1146\/annurev.med.51.1.407","volume":"51","author":"NJ Cox","year":"2000","unstructured":"Cox, N. J. & Subbarao, K. Global epidemiology of influenza: past and present. Annu. Rev. Med. 51, 407\u2013421 (2000).","journal-title":"Annu. Rev. Med."},{"key":"1529_CR2","doi-asserted-by":"crossref","first-page":"eaau5485","DOI":"10.1126\/scitranslmed.aau5485","volume":"11","author":"JK Taubenberger","year":"2019","unstructured":"Taubenberger, J. K., Kash, J. C. & Morens, D. M. The 1918 influenza pandemic: 100 years of questions answered and unanswered. Sci. Transl. Med. 11, eaau5485 (2019).","journal-title":"Sci. Transl. Med."},{"key":"1529_CR3","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1038\/s41586-022-04690-5","volume":"605","author":"MM DeGrace","year":"2022","unstructured":"DeGrace, M. M. et al. Defining the risk of SARS-CoV-2 variants on immune protection. Nature 605, 640\u2013652 (2022).","journal-title":"Nature"},{"key":"1529_CR4","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-28706-1","volume":"8","author":"E Kirkpatrick","year":"2018","unstructured":"Kirkpatrick, E., Qiu, X., Wilson, P. C., Bahl, J. & Krammer, F. The influenza virus hemagglutinin head evolves faster than the stalk domain. Sci. Rep. 8, 10432 (2018).","journal-title":"Sci. Rep."},{"key":"1529_CR5","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41572-018-0002-y","volume":"4","author":"F Krammer","year":"2018","unstructured":"Krammer, F. et al. Influenza. Nat. Rev. Dis. Prim. 4, 3 (2018).","journal-title":"Nat. Rev. Dis. Prim."},{"key":"1529_CR6","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1093\/infdis\/jiy103","volume":"218","author":"EJ Erbelding","year":"2018","unstructured":"Erbelding, E. J. et al. A universal influenza vaccine: the strategic plan for the National Institute of Allergy and Infectious Diseases. J. Infect. Dis. 218, 347\u2013354 (2018).","journal-title":"J. Infect. Dis."},{"key":"1529_CR7","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/s41573-019-0056-x","volume":"19","author":"C-J Wei","year":"2020","unstructured":"Wei, C.-J. et al. Next-generation influenza vaccines: opportunities and challenges. Nat. Rev. Drug Discov. 19, 239\u2013252 (2020).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1529_CR8","doi-asserted-by":"crossref","first-page":"4800","DOI":"10.1073\/pnas.79.15.4800","volume":"79","author":"M Krystal","year":"1982","unstructured":"Krystal, M., Elliott, R. M., Benz, E. W., Young, J. F. & Palese, P. Evolution of influenza A and B viruses: conservation of structural features in the hemagglutinin genes. Proc. Natl Acad. Sci. USA 79, 4800\u20134804 (1982).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1529_CR9","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.1128\/jvi.67.5.2552-2558.1993","volume":"67","author":"Y Okuno","year":"1993","unstructured":"Okuno, Y., Isegawa, Y., Sasao, F. & Ueda, S. A common neutralizing epitope conserved between the hemagglutinins of influenza A virus H1 and H2 strains. J. Virol. 67, 2552\u20132558 (1993).","journal-title":"J. Virol."},{"key":"1529_CR10","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1126\/science.1171491","volume":"324","author":"DC Ekiert","year":"2009","unstructured":"Ekiert, D. C. et al. Antibody recognition of a highly conserved influenza virus epitope. Science 324, 246\u2013251 (2009).","journal-title":"Science"},{"key":"1529_CR11","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1126\/science.1205669","volume":"333","author":"D Corti","year":"2011","unstructured":"Corti, D. et al. A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins. Science 333, 850\u2013856 (2011).","journal-title":"Science"},{"key":"1529_CR12","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1126\/science.1222908","volume":"337","author":"C Dreyfus","year":"2012","unstructured":"Dreyfus, C. et al. Highly conserved protective epitopes on influenza B viruses. Science 337, 1343\u20131348 (2012).","journal-title":"Science"},{"key":"1529_CR13","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.cell.2016.05.073","volume":"166","author":"NL Kallewaard","year":"2016","unstructured":"Kallewaard, N. L. et al. Structure and function analysis of an antibody recognizing all influenza A subtypes. Cell 166, 596\u2013608 (2016).","journal-title":"Cell"},{"key":"1529_CR14","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1038\/s41591-019-0463-x","volume":"25","author":"S Ng","year":"2019","unstructured":"Ng, S. et al. Novel correlates of protection against pandemic H1N1 influenza A virus infection. Nat. Med. 25, 962\u2013967 (2019).","journal-title":"Nat. Med."},{"key":"1529_CR15","doi-asserted-by":"crossref","first-page":"e1000796","DOI":"10.1371\/journal.ppat.1000796","volume":"6","author":"TT Wang","year":"2010","unstructured":"Wang, T. T. et al. Broadly protective monoclonal antibodies against H3 influenza viruses following sequential immunization with different hemagglutinins. PLoS Pathog. 6, e1000796 (2010).","journal-title":"PLoS Pathog."},{"key":"1529_CR16","doi-asserted-by":"crossref","first-page":"10302","DOI":"10.1128\/JVI.01336-12","volume":"86","author":"F Krammer","year":"2012","unstructured":"Krammer, F., Pica, N., Hai, R., Tan, G. S. & Palese, P. Hemagglutinin stalk-reactive antibodies are boosted following sequential infection with seasonal and pandemic H1N1 influenza virus in mice. J. Virol. 86, 10302\u201310307 (2012).","journal-title":"J. Virol."},{"key":"1529_CR17","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41541-017-0012-x","volume":"2","author":"K Van Reeth","year":"2017","unstructured":"Van Reeth, K. et al. Heterologous prime-boost vaccination with H3N2 influenza viruses of swine favors cross-clade antibody responses and protection. NPJ Vaccines 2, 11 (2017).","journal-title":"NPJ Vaccines"},{"key":"1529_CR18","doi-asserted-by":"crossref","first-page":"4577","DOI":"10.1038\/s41598-018-22874-w","volume":"8","author":"Y Luo","year":"2018","unstructured":"Luo, Y. et al. Sequential Immunizations with heterosubtypic virus-like particles elicit cross protection against divergent influenza A viruses in mice. Sci. Rep. 8, 4577 (2018).","journal-title":"Sci. Rep."},{"key":"1529_CR19","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1038\/s41590-018-0305-x","volume":"20","author":"M Kanekiyo","year":"2019","unstructured":"Kanekiyo, M. et al. Mosaic nanoparticle display of diverse influenza virus hemagglutinins elicits broad B cell responses. Nat. Immunol. 20, 362\u2013372 (2019).","journal-title":"Nat. Immunol."},{"key":"1529_CR20","doi-asserted-by":"crossref","first-page":"e0247963","DOI":"10.1371\/journal.pone.0247963","volume":"16","author":"AA Cohen","year":"2021","unstructured":"Cohen, A. A. et al. Construction, characterization, and immunization of nanoparticles that display a diverse array of influenza HA trimers. PLoS ONE 16, e0247963 (2021).","journal-title":"PLoS ONE"},{"key":"1529_CR21","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/s41591-020-1118-7","volume":"27","author":"R Nachbagauer","year":"2021","unstructured":"Nachbagauer, R. et al. A chimeric hemagglutinin-based universal influenza virus vaccine approach induces broad and long-lasting immunity in a randomized, placebo-controlled phase I trial. Nat. Med. 27, 106\u2013114 (2021).","journal-title":"Nat. Med."},{"key":"1529_CR22","doi-asserted-by":"crossref","first-page":"e129035","DOI":"10.1172\/jci.insight.129035","volume":"4","author":"S Jegaskanda","year":"2019","unstructured":"Jegaskanda, S. et al. Hemagglutinin head-specific responses dominate over stem-specific responses following prime boost with mismatched vaccines. JCI Insight 4, e129035 (2019).","journal-title":"JCI Insight"},{"key":"1529_CR23","doi-asserted-by":"crossref","first-page":"e39075","DOI":"10.1371\/journal.pone.0039075","volume":"7","author":"S-C Lin","year":"2012","unstructured":"Lin, S.-C., Lin, Y.-F., Chong, P. & Wu, S.-C. Broader neutralizing antibodies against H5N1 viruses using prime-boost immunization of hyperglycosylated hemagglutinin DNA and virus-like particles. PLoS ONE 7, e39075 (2012).","journal-title":"PLoS ONE"},{"key":"1529_CR24","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1128\/JVI.02608-13","volume":"88","author":"D Eggink","year":"2014","unstructured":"Eggink, D., Goff, P. H. & Palese, P. Guiding the immune response against influenza virus hemagglutinin toward the conserved stalk domain by hyperglycosylation of the globular head domain. J. Virol. 88, 699\u2013704 (2014).","journal-title":"J. Virol."},{"key":"1529_CR25","doi-asserted-by":"crossref","first-page":"9947","DOI":"10.1073\/pnas.1822062116","volume":"116","author":"PA Weidenbacher","year":"2019","unstructured":"Weidenbacher, P. A. & Kim, P. S. Protect, modify, deprotect (PMD): a strategy for creating vaccines to elicit antibodies targeting a specific epitope. Proc. Natl Acad. Sci. USA 116, 9947\u20139952 (2019).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1529_CR26","first-page":"E2514","volume":"111","author":"VVA Mallajosyula","year":"2014","unstructured":"Mallajosyula, V. V. A. et al. Influenza hemagglutinin stem-fragment immunogen elicits broadly neutralizing antibodies and confers heterologous protection. Proc. Natl Acad. Sci. USA 111, E2514\u2013E2523 (2014).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1529_CR27","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1073\/pnas.1308701110","volume":"111","author":"Y Lu","year":"2014","unstructured":"Lu, Y., Welsh, J. P. & Swartz, J. R. Production and stabilization of the trimeric influenza hemagglutinin stem domain for potentially broadly protective influenza vaccines. Proc. Natl Acad. Sci. USA 111, 125\u2013130 (2014).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1529_CR28","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1038\/nm.3927","volume":"21","author":"HM Yassine","year":"2015","unstructured":"Yassine, H. M. et al. Hemagglutinin-stem nanoparticles generate heterosubtypic influenza protection. Nat. Med. 21, 1065\u20131070 (2015).","journal-title":"Nat. Med."},{"key":"1529_CR29","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1126\/science.aac7263","volume":"349","author":"A Impagliazzo","year":"2015","unstructured":"Impagliazzo, A. et al. A stable trimeric influenza hemagglutinin stem as a broadly protective immunogen. Science 349, 1301\u20131306 (2015).","journal-title":"Science"},{"key":"1529_CR30","first-page":"316ra192","volume":"7","author":"SF Andrews","year":"2015","unstructured":"Andrews, S. F. et al. Immune history profoundly affects broadly protective B cell responses to influenza. Sci. Transl. Med. 7, 316ra192 (2015).","journal-title":"Sci. Transl. Med."},{"key":"1529_CR31","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.str.2022.02.014","volume":"30","author":"QJ Huang","year":"2022","unstructured":"Huang, Q. J. et al. Quantitative structural analysis of influenza virus by cryo-electron tomography and convolutional neural networks. Structure 30, 777\u2013786 (2022).","journal-title":"Structure"},{"key":"1529_CR32","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1038\/s41573-021-00163-y","volume":"20","author":"B Pulendran","year":"2021","unstructured":"Pulendran, B., S Arunachalam, P. & O\u2019Hagan, D. T. Emerging concepts in the science of vaccine adjuvants. Nat. Rev. Drug Discov. 20, 454\u2013475 (2021).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1529_CR33","doi-asserted-by":"crossref","first-page":"6618","DOI":"10.1016\/j.vaccine.2007.06.049","volume":"25","author":"B Hansen","year":"2007","unstructured":"Hansen, B., Sokolovska, A., HogenEsch, H. & Hem, S. L. Relationship between the strength of antigen adsorption to an aluminum-containing adjuvant and the immune response. Vaccine 25, 6618\u20136624 (2007).","journal-title":"Vaccine"},{"key":"1529_CR34","doi-asserted-by":"crossref","first-page":"4362","DOI":"10.1016\/j.vaccine.2013.07.019","volume":"31","author":"F Lu","year":"2013","unstructured":"Lu, F., Boutselis, I., Borch, R. F. & Hogenesch, H. Control of antigen-binding to aluminum adjuvants and the immune response with a novel phosphonate linker. Vaccine 31, 4362\u20134367 (2013).","journal-title":"Vaccine"},{"key":"1529_CR35","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/s41591-020-0753-3","volume":"26","author":"TJ Moyer","year":"2020","unstructured":"Moyer, T. J. et al. Engineered immunogen binding to alum adjuvant enhances humoral immunity. Nat. Med. 26, 430\u2013440 (2020).","journal-title":"Nat. Med."},{"key":"1529_CR36","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/s41591-021-01636-8","volume":"28","author":"SF Andrews","year":"2022","unstructured":"Andrews, S. F. et al. A single residue in influenza virus H2 hemagglutinin enhances the breadth of the B cell response elicited by H2 vaccination. Nat. Med. 28, 373\u2013382 (2022).","journal-title":"Nat. Med."},{"key":"1529_CR37","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/s41590-022-01163-9","volume":"23","author":"C Li","year":"2022","unstructured":"Li, C. et al. Mechanisms of innate and adaptive immunity to the Pfizer-BioNTech BNT162b2 vaccine. Nat. Immunol. 23, 543\u2013555 (2022).","journal-title":"Nat. Immunol."},{"key":"1529_CR38","doi-asserted-by":"crossref","first-page":"108682","DOI":"10.1016\/j.celrep.2020.108682","volume":"34","author":"J Han","year":"2021","unstructured":"Han, J. et al. Polyclonal epitope mapping reveals temporal dynamics and diversity of human antibody responses to H5N1 vaccination. Cell Rep. 34, 108682 (2021).","journal-title":"Cell Rep."},{"key":"1529_CR39","unstructured":"Musunuri, S., Weidenbacher, P. A. B. & Kim, P. S. Bringing immunofocusing into focus. NPJ Vaccines (in the press)."},{"key":"1529_CR40","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/s41591-021-01660-8","volume":"28","author":"KV Houser","year":"2022","unstructured":"Houser, K. V. et al. Safety and immunogenicity of a ferritin nanoparticle H2 influenza vaccine in healthy adults: a phase 1 trial. Nat. Med. 28, 383\u2013391 (2022).","journal-title":"Nat. Med."},{"key":"1529_CR41","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/s41541-018-0089-x","volume":"3","author":"H HogenEsch","year":"2018","unstructured":"HogenEsch, H., O\u2019Hagan, D. T. & Fox, C. B. Optimizing the utilization of aluminum adjuvants in vaccines: you might just get what you want. NPJ Vaccines 3, 51 (2018).","journal-title":"NPJ Vaccines"},{"key":"1529_CR42","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/nrm1052","volume":"4","author":"L Ellgaard","year":"2003","unstructured":"Ellgaard, L. & Helenius, A. Quality control in the endoplasmic reticulum. Nat. Rev. Mol. Cell Biol. 4, 181\u2013191 (2003).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"1529_CR43","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1073\/pnas.1519214113","volume":"113","author":"G Veggiani","year":"2016","unstructured":"Veggiani, G. et al. Programmable polyproteams built using twin peptide superglues. Proc. Natl Acad. Sci. USA 113, 1202\u20131207 (2016).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1529_CR44","doi-asserted-by":"crossref","first-page":"8855","DOI":"10.1021\/acsnano.8b02805","volume":"12","author":"TUJ Bruun","year":"2018","unstructured":"Bruun, T. U. J., Andersson, A.-M. C., Draper, S. J. & Howarth, M. Engineering a rugged nanoscaffold to enhance plug-and-display vaccination. ACS Nano 12, 8855\u20138866 (2018).","journal-title":"ACS Nano"},{"key":"1529_CR45","doi-asserted-by":"crossref","first-page":"e2202729","DOI":"10.1002\/adhm.202202729","volume":"12","author":"SJ Frey","year":"2023","unstructured":"Frey, S. J. et al. Nanovaccines displaying the influenza virus hemagglutinin in an inverted orientation elicit an enhanced stalk-directed antibody response. Adv. Healthc. Mater. 12, e2202729 (2023).","journal-title":"Adv. Healthc. Mater."},{"key":"1529_CR46","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1126\/science.aad6117","volume":"351","author":"J Misasi","year":"2016","unstructured":"Misasi, J. et al. Structural and molecular basis for Ebola virus neutralization by protective human antibodies. Science 351, 1343\u20131346 (2016).","journal-title":"Science"},{"key":"1529_CR47","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/j.jmb.2004.09.079","volume":"344","author":"S Meier","year":"2004","unstructured":"Meier, S., G\u00fcthe, S., Kiefhaber, T. & Grzesiek, S. Foldon, the natural trimerization domain of T4 fibritin, dissociates into a monomeric A-state form containing a stable \u03b2-hairpin: atomic details of trimer dissociation and local \u03b2-hairpin stability from residual dipolar couplings. J. Mol. Biol. 344, 1051\u20131069 (2004).","journal-title":"J. Mol. Biol."},{"key":"1529_CR48","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1110\/ps.8.4.921","volume":"8","author":"D Beckett","year":"1999","unstructured":"Beckett, D., Kovaleva, E. & Schatz, P. J. A minimal peptide substrate in biotin holoenzyme synthetase-catalyzed biotinylation. Protein Sci. 8, 921\u2013929 (1999).","journal-title":"Protein Sci."},{"key":"1529_CR49","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1021\/acscentsci.0c01405","volume":"7","author":"AE Powell","year":"2021","unstructured":"Powell, A. E. et al. A single immunization with spike-functionalized ferritin vaccines elicits neutralizing antibody responses against SARS-CoV-2 in mice. ACS Cent. Sci. 7, 183\u2013199 (2021).","journal-title":"ACS Cent. Sci."},{"key":"1529_CR50","doi-asserted-by":"crossref","first-page":"513","DOI":"10.3390\/v12050513","volume":"12","author":"KHD Crawford","year":"2020","unstructured":"Crawford, K. H. D. et al. protocol and reagents for pseudotyping lentiviral particles with SARS-CoV-2 spike protein for neutralization assays. Viruses 12, 513 (2020).","journal-title":"Viruses"},{"key":"1529_CR51","doi-asserted-by":"crossref","first-page":"e465","DOI":"10.1002\/cpz1.465","volume":"2","author":"F Cuevas","year":"2022","unstructured":"Cuevas, F., Kawabata, H., Krammer, F. & Carre\u00f1o, J. M. An in vitro microneutralization assay for influenza virus serology. Curr. Protoc. 2, e465 (2022).","journal-title":"Curr. Protoc."},{"key":"1529_CR52","doi-asserted-by":"crossref","first-page":"e42166","DOI":"10.7554\/eLife.42166","volume":"7","author":"J Zivanov","year":"2018","unstructured":"Zivanov, J. et al. New tools for automated high-resolution cryo-EM structure determination in RELION-3. eLife 7, e42166 (2018).","journal-title":"eLife"},{"key":"1529_CR53","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/nmeth.4169","volume":"14","author":"A Punjani","year":"2017","unstructured":"Punjani, A., Rubinstein, J. L., Fleet, D. J. & Brubaker, M. A. cryoSPARC: algorithms for rapid unsupervised cryo-EM structure determination. Nat. Methods 14, 290\u2013296 (2017).","journal-title":"Nat. Methods"},{"key":"1529_CR54","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/j.cell.2020.06.025","volume":"182","author":"CO Barnes","year":"2020","unstructured":"Barnes, C. O. et al. Structures of human antibodies bound to SARS-CoV-2 spike reveal common epitopes and recurrent features of antibodies. Cell 182, 828\u2013842 (2020).","journal-title":"Cell"},{"key":"1529_CR55","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1002\/pro.3943","volume":"30","author":"EF Pettersen","year":"2021","unstructured":"Pettersen, E. F. et al. UCSF ChimeraX: structure visualization for researchers, educators, and developers. Protein Sci. 30, 70\u201382 (2021).","journal-title":"Protein Sci."}],"container-title":["Nature Chemical Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41589-023-01529-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41589-023-01529-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41589-023-01529-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,30]],"date-time":"2024-07-30T16:04:28Z","timestamp":1722355468000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41589-023-01529-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,15]]},"references-count":55,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["1529"],"URL":"https:\/\/doi.org\/10.1038\/s41589-023-01529-6","relation":{},"ISSN":["1552-4450","1552-4469"],"issn-type":[{"value":"1552-4450","type":"print"},{"value":"1552-4469","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,15]]},"assertion":[{"value":"7 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 December 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"D.X., P.A.B.W. and P.S.K. are named as inventors on a patent application applied for by Stanford University and the Chan Zuckerberg Biohub on engineering antigen binding and orientation on alum adjuvants. P.A.B.W. is an employee of Vaccine Company, Inc., and P.S.K. is a co-founder and member of the Board of Directors of Vaccine Company, Inc. All other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}